Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic

Jason Boehme, Natacha Le Moan, Rebecca J. Kameny, Alexandra Loucks, Michael J. Johengen, Amy L. Lesneski, Wenhui Gong, Brian D. Goudy, Tina Davis, Kevin Tanaka, Andrew Davis, Youping He, Janel Long-Boyle, Vijay Ivaturi, Jogarao V.S. Gobburu, Jonathan A. Winger, Stephen P. Cary, Sanjeev A. Datar, Jeffrey R. Fineman, Ana KrtolicaEmin Maltepe

Research output: Contribution to journalArticle

Abstract

The heart exhibits the highest basal oxygen (O2) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a compensatory increase in cardiac output that further increases myocardial O2 demand, predisposing the heart to ischemic stress and myocardial dysfunction. Here, we test the utility of a novel engineered protein derived from the heme-based nitric oxide (NO)/oxygen (H-NOX) family of bacterial proteins as an O2 delivery biotherapeutic (Omniox-cardiovascular [OMX-CV]) for the hypoxic myocardium. Because of their unique binding characteristics, H-NOX-based variants effectively deliver O2 to hypoxic tissues, but not those at physiologic O2 tension. Additionally, H-NOX-based variants exhibit tunable binding that is specific for O2 with subphysiologic reactivity towards NO, circumventing a significant toxicity exhibited by hemoglobin (Hb)-based O2 carriers (HBOCs). Juvenile lambs were sedated, mechanically ventilated, and instrumented to measure cardiovascular parameters. Biventricular admittance catheters were inserted to perform pressure-volume (PV) analyses. Systemic hypoxia was induced by ventilation with 10% O2. Following 15 minutes of hypoxia, the lambs were treated with OMX-CV (200 mg/kg IV) or vehicle. Acute hypoxia induced significant increases in heart rate (HR), pulmonary blood flow (PBF), and pulmonary vascular resistance (PVR) (p < 0.05). At 1 hour, vehicle-treated lambs exhibited severe hypoxia and a significant decrease in biventricular contractile function. However, in OMX-CV-treated animals, myocardial oxygenation was improved without negatively impacting systemic or PVR, and both right ventricle (RV) and left ventricle (LV) contractile function were maintained at pre-hypoxic baseline levels. These data suggest that OMX-CV is a promising and safe O2 delivery biotherapeutic for the preservation of myocardial contractility in the setting of acute hypoxia.

Original languageEnglish (US)
Pages (from-to)e2005924
JournalPLoS biology
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Fingerprint

hypoxia
Oxygen
oxygen
Vascular Resistance
Nitric Oxide
lambs
Tissue
lungs
Bacterial Proteins
Oxygenation
blood vessels
Catheters
Heart Ventricles
nitric oxide
Heme
Metabolism
Ventilation
heart
Toxicity
Hemoglobins

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Boehme, J., Le Moan, N., Kameny, R. J., Loucks, A., Johengen, M. J., Lesneski, A. L., ... Maltepe, E. (2018). Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. PLoS biology, 16(10), e2005924. https://doi.org/10.1371/journal.pbio.2005924

Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. / Boehme, Jason; Le Moan, Natacha; Kameny, Rebecca J.; Loucks, Alexandra; Johengen, Michael J.; Lesneski, Amy L.; Gong, Wenhui; Goudy, Brian D.; Davis, Tina; Tanaka, Kevin; Davis, Andrew; He, Youping; Long-Boyle, Janel; Ivaturi, Vijay; Gobburu, Jogarao V.S.; Winger, Jonathan A.; Cary, Stephen P.; Datar, Sanjeev A.; Fineman, Jeffrey R.; Krtolica, Ana; Maltepe, Emin.

In: PLoS biology, Vol. 16, No. 10, 01.10.2018, p. e2005924.

Research output: Contribution to journalArticle

Boehme, J, Le Moan, N, Kameny, RJ, Loucks, A, Johengen, MJ, Lesneski, AL, Gong, W, Goudy, BD, Davis, T, Tanaka, K, Davis, A, He, Y, Long-Boyle, J, Ivaturi, V, Gobburu, JVS, Winger, JA, Cary, SP, Datar, SA, Fineman, JR, Krtolica, A & Maltepe, E 2018, 'Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic', PLoS biology, vol. 16, no. 10, pp. e2005924. https://doi.org/10.1371/journal.pbio.2005924
Boehme, Jason ; Le Moan, Natacha ; Kameny, Rebecca J. ; Loucks, Alexandra ; Johengen, Michael J. ; Lesneski, Amy L. ; Gong, Wenhui ; Goudy, Brian D. ; Davis, Tina ; Tanaka, Kevin ; Davis, Andrew ; He, Youping ; Long-Boyle, Janel ; Ivaturi, Vijay ; Gobburu, Jogarao V.S. ; Winger, Jonathan A. ; Cary, Stephen P. ; Datar, Sanjeev A. ; Fineman, Jeffrey R. ; Krtolica, Ana ; Maltepe, Emin. / Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic. In: PLoS biology. 2018 ; Vol. 16, No. 10. pp. e2005924.
@article{7d4eb62c3a4a47f7b53dbdd20cb6eb39,
title = "Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic",
abstract = "The heart exhibits the highest basal oxygen (O2) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a compensatory increase in cardiac output that further increases myocardial O2 demand, predisposing the heart to ischemic stress and myocardial dysfunction. Here, we test the utility of a novel engineered protein derived from the heme-based nitric oxide (NO)/oxygen (H-NOX) family of bacterial proteins as an O2 delivery biotherapeutic (Omniox-cardiovascular [OMX-CV]) for the hypoxic myocardium. Because of their unique binding characteristics, H-NOX-based variants effectively deliver O2 to hypoxic tissues, but not those at physiologic O2 tension. Additionally, H-NOX-based variants exhibit tunable binding that is specific for O2 with subphysiologic reactivity towards NO, circumventing a significant toxicity exhibited by hemoglobin (Hb)-based O2 carriers (HBOCs). Juvenile lambs were sedated, mechanically ventilated, and instrumented to measure cardiovascular parameters. Biventricular admittance catheters were inserted to perform pressure-volume (PV) analyses. Systemic hypoxia was induced by ventilation with 10{\%} O2. Following 15 minutes of hypoxia, the lambs were treated with OMX-CV (200 mg/kg IV) or vehicle. Acute hypoxia induced significant increases in heart rate (HR), pulmonary blood flow (PBF), and pulmonary vascular resistance (PVR) (p < 0.05). At 1 hour, vehicle-treated lambs exhibited severe hypoxia and a significant decrease in biventricular contractile function. However, in OMX-CV-treated animals, myocardial oxygenation was improved without negatively impacting systemic or PVR, and both right ventricle (RV) and left ventricle (LV) contractile function were maintained at pre-hypoxic baseline levels. These data suggest that OMX-CV is a promising and safe O2 delivery biotherapeutic for the preservation of myocardial contractility in the setting of acute hypoxia.",
author = "Jason Boehme and {Le Moan}, Natacha and Kameny, {Rebecca J.} and Alexandra Loucks and Johengen, {Michael J.} and Lesneski, {Amy L.} and Wenhui Gong and Goudy, {Brian D.} and Tina Davis and Kevin Tanaka and Andrew Davis and Youping He and Janel Long-Boyle and Vijay Ivaturi and Gobburu, {Jogarao V.S.} and Winger, {Jonathan A.} and Cary, {Stephen P.} and Datar, {Sanjeev A.} and Fineman, {Jeffrey R.} and Ana Krtolica and Emin Maltepe",
year = "2018",
month = "10",
day = "1",
doi = "10.1371/journal.pbio.2005924",
language = "English (US)",
volume = "16",
pages = "e2005924",
journal = "PLoS Biology",
issn = "1544-9173",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic

AU - Boehme, Jason

AU - Le Moan, Natacha

AU - Kameny, Rebecca J.

AU - Loucks, Alexandra

AU - Johengen, Michael J.

AU - Lesneski, Amy L.

AU - Gong, Wenhui

AU - Goudy, Brian D.

AU - Davis, Tina

AU - Tanaka, Kevin

AU - Davis, Andrew

AU - He, Youping

AU - Long-Boyle, Janel

AU - Ivaturi, Vijay

AU - Gobburu, Jogarao V.S.

AU - Winger, Jonathan A.

AU - Cary, Stephen P.

AU - Datar, Sanjeev A.

AU - Fineman, Jeffrey R.

AU - Krtolica, Ana

AU - Maltepe, Emin

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The heart exhibits the highest basal oxygen (O2) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a compensatory increase in cardiac output that further increases myocardial O2 demand, predisposing the heart to ischemic stress and myocardial dysfunction. Here, we test the utility of a novel engineered protein derived from the heme-based nitric oxide (NO)/oxygen (H-NOX) family of bacterial proteins as an O2 delivery biotherapeutic (Omniox-cardiovascular [OMX-CV]) for the hypoxic myocardium. Because of their unique binding characteristics, H-NOX-based variants effectively deliver O2 to hypoxic tissues, but not those at physiologic O2 tension. Additionally, H-NOX-based variants exhibit tunable binding that is specific for O2 with subphysiologic reactivity towards NO, circumventing a significant toxicity exhibited by hemoglobin (Hb)-based O2 carriers (HBOCs). Juvenile lambs were sedated, mechanically ventilated, and instrumented to measure cardiovascular parameters. Biventricular admittance catheters were inserted to perform pressure-volume (PV) analyses. Systemic hypoxia was induced by ventilation with 10% O2. Following 15 minutes of hypoxia, the lambs were treated with OMX-CV (200 mg/kg IV) or vehicle. Acute hypoxia induced significant increases in heart rate (HR), pulmonary blood flow (PBF), and pulmonary vascular resistance (PVR) (p < 0.05). At 1 hour, vehicle-treated lambs exhibited severe hypoxia and a significant decrease in biventricular contractile function. However, in OMX-CV-treated animals, myocardial oxygenation was improved without negatively impacting systemic or PVR, and both right ventricle (RV) and left ventricle (LV) contractile function were maintained at pre-hypoxic baseline levels. These data suggest that OMX-CV is a promising and safe O2 delivery biotherapeutic for the preservation of myocardial contractility in the setting of acute hypoxia.

AB - The heart exhibits the highest basal oxygen (O2) consumption per tissue mass of any organ in the body and is uniquely dependent on aerobic metabolism to sustain contractile function. During acute hypoxic states, the body responds with a compensatory increase in cardiac output that further increases myocardial O2 demand, predisposing the heart to ischemic stress and myocardial dysfunction. Here, we test the utility of a novel engineered protein derived from the heme-based nitric oxide (NO)/oxygen (H-NOX) family of bacterial proteins as an O2 delivery biotherapeutic (Omniox-cardiovascular [OMX-CV]) for the hypoxic myocardium. Because of their unique binding characteristics, H-NOX-based variants effectively deliver O2 to hypoxic tissues, but not those at physiologic O2 tension. Additionally, H-NOX-based variants exhibit tunable binding that is specific for O2 with subphysiologic reactivity towards NO, circumventing a significant toxicity exhibited by hemoglobin (Hb)-based O2 carriers (HBOCs). Juvenile lambs were sedated, mechanically ventilated, and instrumented to measure cardiovascular parameters. Biventricular admittance catheters were inserted to perform pressure-volume (PV) analyses. Systemic hypoxia was induced by ventilation with 10% O2. Following 15 minutes of hypoxia, the lambs were treated with OMX-CV (200 mg/kg IV) or vehicle. Acute hypoxia induced significant increases in heart rate (HR), pulmonary blood flow (PBF), and pulmonary vascular resistance (PVR) (p < 0.05). At 1 hour, vehicle-treated lambs exhibited severe hypoxia and a significant decrease in biventricular contractile function. However, in OMX-CV-treated animals, myocardial oxygenation was improved without negatively impacting systemic or PVR, and both right ventricle (RV) and left ventricle (LV) contractile function were maintained at pre-hypoxic baseline levels. These data suggest that OMX-CV is a promising and safe O2 delivery biotherapeutic for the preservation of myocardial contractility in the setting of acute hypoxia.

UR - http://www.scopus.com/inward/record.url?scp=85055079275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055079275&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.2005924

DO - 10.1371/journal.pbio.2005924

M3 - Article

C2 - 30335746

AN - SCOPUS:85055079275

VL - 16

SP - e2005924

JO - PLoS Biology

JF - PLoS Biology

SN - 1544-9173

IS - 10

ER -